BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8603454)

  • 1. Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer.
    Murren JR; Durivage HJ; Buzaid AC; Reiss M; Flynn SD; Carter D; Hait WN
    Cancer Chemother Pharmacol; 1996; 38(1):65-70. PubMed ID: 8603454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
    Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
    Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance in chemotherapy for breast cancer.
    Saeki T; Tsuruo T; Sato W; Nishikawsa K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
    Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
    Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
    Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
    Walker J; Martin C; Callaghan R
    Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.
    Cowan KH; Moscow JA; Huang H; Zujewski JA; O'Shaughnessy J; Sorrentino B; Hines K; Carter C; Schneider E; Cusack G; Noone M; Dunbar C; Steinberg S; Wilson W; Goldspiel B; Read EJ; Leitman SF; McDonagh K; Chow C; Abati A; Chiang Y; Chang YN; Gottesman MM; Pastan I; Nienhuis A
    Clin Cancer Res; 1999 Jul; 5(7):1619-28. PubMed ID: 10430060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.
    Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY
    Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer.
    Fraschini G; Fleishman G; Charnsangavej C; Carrasco CH; Hortobagyi GN
    Cancer Treat Rep; 1987 Nov; 71(11):1001-5. PubMed ID: 3677109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
    Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer.
    Yap HY; Blumenschein GR; Hortobagyi GN; Buzdar AU; Schell FC; Bodey GP
    Am J Clin Oncol; 1982 Oct; 5(5):511-4. PubMed ID: 7180829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine as palliative therapy in advanced breast cancer.
    Gasco M; Gardin G; Repetto L; Campora E; Rosso R
    Anticancer Res; 1997; 17(2B):1431-3. PubMed ID: 9137510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer.
    Bates SE; Meadows B; Goldspiel BR; Denicoff A; Le TB; Tucker E; Steinberg SM; Elwood LJ
    Cancer Chemother Pharmacol; 1995; 35(6):457-63. PubMed ID: 7882454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer.
    Yap HY; Blumenschein GR; Keating MJ; Hortobagyi GN; Tashima CK; Loo TL
    Cancer Treat Rep; 1980; 64(2-3):279-83. PubMed ID: 7407762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of steroidal alkaloids on drug transport and multidrug resistance in human cancer cells.
    Lavie Y; Harel-Orbital T; Gaffield W; Liscovitch M
    Anticancer Res; 2001; 21(2A):1189-94. PubMed ID: 11396162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
    Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
    J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.